Study sends strong signal not to sequence immune checkpoint inhibitors in advanced kidney cancer
Study Title: Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor treatment in metastatic renal cell carcinoma: primary PFS analysis from the Phase 3, randomized, open-label CONTACT-03 study
Publication: ASCO Annual Meeting: Abstract LBA4500, Oral Abstract Session: Genitourinary Cancer – Kidney and Bladder – Monday, June 5, 2023, 12:30pm ET
The Lancet: Monday, June 5, 2023, 8:00am ET
Dana-Farber Cancer Institute presenting author: Toni K Choueiri, MD
City of Hope senior author: Sumanta K. Pal, MD
Patients with advanced kidney cancer are routinely given immune checkpoint inhibitors (ICIs) as first-line treatment. The CONTACT-03, phase 3 clinical trial tested the effects of giving ICIs again, as part of a standard second-line therapy. It is the first trial of its kind to compare a standard therapy alone (cabozantinib) to standard therapy plus an ICI (atezolizumab plus cabozantinib) in solid tumors that have progressed after first-line therapy with an ICI. Patients taking atezolizumab plus cabozantinib did not experience longer progression free survival or overall survival compared with those taking cabozantinib alone. An examination of subgroups of patients based on prior treatment regimens and risk groups showed no benefit of the addition to any group. Further, patients taking the combination therapy experienced higher levels of toxicity.
Immune checkpoint inhibitors such as those that block PD-1 and PD-L1 have revolutionized cancer therapy and become part of standard first-line therapy for many solid tumors, including for advanced kidney cancer. An emerging practice for these patients includes continuing or rechallenging with these drugs if the cancer progresses. This study is the first to rigorously assess the safety and efficacy of that practice in a phase 3 randomized clinical trial. The results send a strong signal not to sequence PD-1/L1 inhibitors in these patients because it provides no clinical benefit and could introduce potential harm.
This study was sponsored by F. Hoffmann-La Roche. Exelixis was a study collaborator.